Cyclerion Historical Income Statement
| CYCN Stock | USD 2.75 0.18 6.14% |
Historical analysis of Cyclerion Therapeutics income statement accounts such as Interest Expense of 355 K, Selling General Administrative of 16.2 M or Total Revenue of 0.0 can show how well Cyclerion Therapeutics performed in making a profits. Evaluating Cyclerion Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cyclerion Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cyclerion Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclerion Therapeutics is a good buy for the upcoming year.
Cyclerion |
About Cyclerion Income Statement Analysis
Cyclerion Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cyclerion Therapeutics shareholders. The income statement also shows Cyclerion investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cyclerion Therapeutics Income Statement Chart
Add Fundamental
Most accounts from Cyclerion Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cyclerion Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.At this time, Cyclerion Therapeutics' Interest Expense is very stable compared to the past year. As of the 23rd of September 2024, Selling General Administrative is likely to grow to about 16.2 M, while Total Revenue is likely to drop 0.00.
Cyclerion Therapeutics income statement Correlations
Click cells to compare fundamentals
Cyclerion Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclerion Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Selling General Administrative | 34.4M | 28.8M | 20.6M | 14.5M | 8.1M | 16.2M | |
| Gross Profit | 4.5M | 2.3M | 2.8M | 232K | 266.8K | 253.5K | |
| Other Operating Expenses | 129.5M | 85.2M | 57.6M | 44.7M | 9.6M | 9.2M | |
| Operating Income | (125.0M) | (81.3M) | (55.2M) | (44.4M) | (9.6M) | (10.1M) | |
| Net Income From Continuing Ops | (123.0M) | (80.7M) | (51.6M) | (44.1M) | (41.1M) | (43.1M) | |
| Ebit | (125.0M) | (87.5M) | (54.3M) | (44.4M) | (9.8M) | (10.3M) | |
| Research Development | 95.1M | 56.4M | 37.6M | 31.5M | 1.5M | 1.4M | |
| Total Operating Expenses | 129.5M | 85.2M | 57.6M | 44.7M | 9.6M | 9.2M | |
| Income Before Tax | (123.0M) | (77.8M) | (51.6M) | (44.1M) | (12.6M) | (13.2M) | |
| Total Other Income Expense Net | 2.0M | 3.5M | 3.5M | 294K | (2.9M) | (2.8M) | |
| Net Income Applicable To Common Shares | (123.0M) | (77.8M) | (51.6M) | (44.1M) | (50.7M) | (53.2M) | |
| Net Income | (121.0M) | (72.7M) | (51.7M) | (43.8M) | (21.0M) | (22.1M) | |
| Income Tax Expense | (2.0M) | (5.1M) | 16K | (294K) | 8.4M | 8.8M | |
| Depreciation And Amortization | 2.7M | 2.3M | 472K | 65K | 167.9K | 159.5K | |
| Ebitda | (122.3M) | (85.2M) | (53.8M) | (44.3M) | (9.6M) | (10.1M) | |
| Reconciled Depreciation | 1.5M | 2.7M | 2.3M | 472K | 65K | 0.0 |
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
| 0.52 | MBIO | Mustang Bio | PairCorr |
| 0.45 | RANI | Rani Therapeutics | PairCorr |
| 0.41 | REVBW | Revelation Biosciences | PairCorr |
| 0.36 | DYAI | Dyadic International | PairCorr |
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Cyclerion Stock
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.